Home/Pipeline/Enitociclib (VIP152)

Enitociclib (VIP152)

Non-Hodgkin Lymphoma (NHL)

Phase 1Previously Active

Key Facts

Indication
Non-Hodgkin Lymphoma (NHL)
Phase
Phase 1
Status
Previously Active
Company

About Vincerx Pharma

Vincerx Pharma is a NASDAQ-listed biotech (VINC) with a mission to address high unmet needs in oncology by developing novel therapeutics. The company employs a capital-efficient, virtual R&D model to in-license and advance a pipeline of targeted and immuno-oncology candidates. Its strategy centers on precise asset selection, biomarker-driven development, and exploring combination regimens to overcome therapeutic resistance. Despite facing significant financial and operational challenges common to early-stage biotechs, Vincerx aims to create value through disciplined pipeline progression and strategic partnerships.

View full company profile

Therapeutic Areas